London
· Delayed Price · Currency is GBP · Price in USD Myriad Genetics Company Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally.
It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer.
It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus.
It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions.
It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer.
The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
| Country | United States |
| Founded | 1992 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 2,700 |
| CEO | Paul Diaz |
Contact Details
Address: 322 North 2200 West Salt Lake City, Delaware 84116 United States | |
| Phone | 801 584 3600 |
| Website | myriad.com |
Stock Details
| Ticker Symbol | 0K3W |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US62855J1043 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Paul J. Diaz | Chief Executive Officer, President and Director |
| R. Bryan Riggsbee | Executive Vice President, Chief Financial Officer and Treasurer |
| Nicole Lambert | Chief Operating Officer |
| Mark S. Verratti | President of Myriad Neuroscience and Autoimmune |
| Dr. Kevin Richard Haas | Chief Technology Officer |
| Dale Muzzey Ph.D. | Senior Vice President of Research & Development and Interim Chief Scientific Officer |
| Scott Gleason | Senior Vice President of Investor Relations |
| Nathan Smith | Senior Vice President of Investor Relations and Treasury |
| Dr. Clivetty Martinez | Chief Compliance Officer |
| Pamela Wong | Chief Legal Officer |